Select Language
VEGF R3
VEGF R3 Overview
| English Name | Vascular endothelial growth factor receptor 3 | Approved Drugs | 14 |
| Drugs in Clinical Trials | 22 | Target Synonym | LMPHM1，Primary Congenital Lymphedema，Fms Related Receptor Tyrosine Kinase 4，VEGF Receptor-3，Feline McDonough Sarcoma (FMS)-Like Tyrosine Kinase 4，VEGFR3，VEGFR-3，FLT4，Vascular endothelial growth factor receptor 3，Fms Related Tyrosine Kinase 4，Tyrosine-Protein Kinase Receptor FLT4，Fms-Like Tyrosine Kinase 4，FLT-4，Fms-Related Tyrosine Kinase 4，LMPH1A，FLT41，PCL，Vascular Endothelial Growth Factor Receptor-3，CHTD7 |
| Highest Development Stage | Approved | ||
| English Name | Vascular endothelial growth factor receptor 3 |
| Target Synonym | LMPHM1，Primary Congenital Lymphedema，Fms Related Receptor Tyrosine Kinase 4，VEGF Receptor-3，Feline McDonough Sarcoma (FMS)-Like Tyrosine Kinase 4，VEGFR3，VEGFR-3，FLT4，Vascular endothelial growth factor receptor 3，Fms Related Tyrosine Kinase 4，Tyrosine-Protein Kinase Receptor FLT4，Fms-Like Tyrosine Kinase 4，FLT-4，Fms-Related Tyrosine Kinase 4，LMPH1A，FLT41，PCL，Vascular Endothelial Growth Factor Receptor-3，CHTD7 |
| Approved Drugs | 14 |
| Drugs in Clinical Trials | 22 |
| Highest Development Stage | Approved |
VEGF R3 Product List
- Product Category
Protein (4)
- Product Status
Launched (4)
- Species
Human (3)Mouse (1)
- Tag
Fc Tag (1)His Tag & Avi Tag (1)Mouse IgG Fc Tag (1)His Tag (1)
- Conjugate
Unconjugated (3)Biotin-labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT FL4-H5251 |  Human | HEK293 | Human VEGF R3 / FLT4 Protein, Fc Tag (MALS verified) |  |  |  |  Add to Cart |
FL4-H52H3 | Human | HEK293 | Human VEGF R3 / FLT4 Protein, His Tag (MALS verified) |  | | Add to Cart | |
FL4-H82E1 | Human | HEK293 | Biotinylated Human VEGF R3 / FLT4 Protein, His,Avitag™ |  | | | Add to Cart |
FL4-M5251 |  Mouse | HEK293 | Mouse VEGF R3 / FLT4 Protein, Mouse IgG2a Fc Tag, low endotoxin |  | | | Add to Cart |
Total: 4
- 1
VEGF R3 Background
Vascular endothelial growth factor receptor 3 (VEGF R3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). VEGF R3 mediates lymphangiogenesis in response to VEGF-C and VEGF-D. VEGF R3 is widely expressed in the early embryo but becomes restricted to lymphatic endothelia at later stages of development. It is likely that VEGF R3 may be important for lymph angiogenesis.
VEGF R3 Synonyms
Flt-4,FLT4,LMPH1A,PCLFLT41,VEGFR3,VEGFR-3,FLT-4,FLT-41,FLT41,PCL
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Cediranib | AZD2171; AZD-2171; NSC-732208 | Phase 3 Clinical | Astrazeneca Plc | Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenocarcinoma, Mucinous; Angioimmunoblastic T-cell Lymphoma; Ascites; Astrocytoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Burkitt Lymphoma; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Carcinosarcoma; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Ependymoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Glioma; Gliosarcoma; Head and Neck Neoplasms; Hepatic Insufficiency; Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypopharyngeal Neoplasms; Intraocular Lymphoma; L | Details |
| Sitravatinib | MG-516; MG-91516; MGCD-516; IND-155305; MGCD-0516 | Phase 3 Clinical | Mirati Therapeutics Inc | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Hepatic Insufficiency; Kidney Neoplasms; Liposarcoma; Lung Diseases; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Oral Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Ureteral Neoplasms; Uterine Cervical Neoplasms; Uveal melanoma | Details |
| Axitinib intravitreal implant (Ocular Therapeutix) | OTX-TKI | Phase 3 Clinical | Ocular Therapeutix Inc | Diabetic Retinopathy; Macular Degeneration; Wet Macular Degeneration | Details |
| AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pulmonary Fibrosis; Solid tumours; Urinary Bladder Neoplasms | Details |
| Lucitanib | S-80881; AL-3810; CO-3810; E-3810; S-80881-2 | Phase 2 Clinical | Advenchen Laboratories Nanjing Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Metastatic breast cancer; Nasopharyngeal Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Thymus Neoplasms | Details |
| Telatinib | EOC-315; BAY-57-9352 | Phase 2 Clinical | Bayer AG | Solid tumours; Stomach Neoplasms | Details |
| Inhaled Nintedanib – dry powder (Avalyn Pharma) | AP02; AP 02 DP; AP-02; AP02-DP | Phase 2 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Respiratory Tract Diseases | Details |
| Axitinib Implant（Aerie） | AR-14034 SR; AR-14034 | Phase 2 Clinical | Aerie Pharmaceuticals Inc | Macular Degeneration | Details |
| K-13 | Phase 2 Clinical | Shanghai Yifeng Biotechnology Co Ltd | Neoplasms; Solid tumours | Details | |
| Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
| KHK-4951 | Phase 2 Clinical | Kyowa Kirin | Diabetic macular oedema; Macular Degeneration; Macular Edema; Wet Macular Degeneration | Details | |
| Axitinib injectable suspension (Clearside Biomedical) | CLS-1002; CLS-011-A; CLS011A; CLS-AX | Phase 2 Clinical | Clearside Biomedical Inc | Macular Degeneration | Details |
| Hydroxychloroquine/Sorafenib | Phase 2 Clinical | Vg Life Sciences | Ovarian Neoplasms; Solid tumours | Details | |
| nintedanib (Avalyn Pharma) | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details | |
| Tafetinib Malate | SIM-0702; SIM-1005; SIM-010603 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Jilin Boda Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd | Neoplasms | Details |
| Nintedanib Esylate Inhalation Powder(Cspc) | Phase 1 Clinical | Cspc-Nbp Pharmaceutical Co Ltd | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details | |
| DPH-001 | DPH-001; DPH001 | Phase 1 Clinical | Disruptive Pharma AB | Details | |
| MNKD-201 | MNKD-201; MKND-201 | Phase 1 Clinical | MannKind Corp | Idiopathic Pulmonary Fibrosis | Details |
| RP-904 | Phase 1 Clinical | Risen (Suzhou) Pharma Tech Co Ltd | Solid tumours | Details | |
| EVT-801 | EVT-801 | Phase 1 Clinical | Sanofi Sa (Sanofi Ag) | Solid tumours | Details |
| ICP-033 | ICP-033 | Phase 1 Clinical | Beijing Innocare Pharma Tech Co Ltd | Solid tumours | Details |
| Sorafenib tosylate (Bio-Synectics) | BS-104 | Clinical | Bio-Synectics Inc | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Bile Duct Diseases; Bone Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Craniopharyngioma; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Gastroesophageal Junction Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Head and Neck Neoplasms; Hepatic Insufficiency; Leiomyosarcoma; Liver Dysfunction; Lung Diseases, Interstitial; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Medullary thyroid cancer (MTC); Melanoma; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Neuroendocrine Tumors; Osteoma; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma; Sarcoma, Alveolar Soft Part; Sarcoma, Synovial; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Thoracic Neoplasms; Thyroid Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | Details |
| Lenvatinib Mesilate | E-7080; MK-7902; ER-203492-00 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Follicular; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Hepatic Insufficiency; Liver Diseases; Liver Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Paraganglioma; Pheochromocytoma; Renal Insufficiency; Solid tumours; Stomach Neoplasms; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Uterine Cervical Neoplasms | Details |
| Axitinib | PF-01367866; AG-13736; AG-013736 | Approved | Pfizer Inc | 英立达, Inlyta | United States | Carcinoma, Renal Cell | Pf Prism Cv | 2012-01-27 | Adenocarcinoma; Adrenal Cortex Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Ductal; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Glioblastoma; Hepatic Insufficiency; Kidney Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Melanoma; Mesothelioma; Myelodysplastic Syndromes; Nasopharyngeal Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Paraganglioma; Pheochromocytoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Uveal melanoma | Details |
| Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Adenocarcinoma; Adenoma; Bile Duct Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastrinoma; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glucagonoma; Hemangiosarcoma; Insulinoma; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Melanoma; Meningioma; Neoplasm Metastasis; Neoplasms; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Sarcoma; Sarcoma, Ewing; Solid tumours; Somatostatinoma; Stomach Neoplasms; Thymoma; Thyroid Neoplasms | Details |
| Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim International Gmbh | 2014-10-15 | Adenocarcinoma, Clear Cell; Appendiceal Neoplasms; Asbestosis; Astrocytoma; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Endometrial Stromal Tumors; Esophageal Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Glioblastoma; Gliosarcoma; Hepatic Insufficiency; Idiopathic Pulmonary Fibrosis; Leukemia, Myeloid, Acute; Lung Diseases, Interstitial; Mesothelioma; Multiple Myeloma; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Pulmonary Fibrosis; Radiation Pneumonitis; Rejection of lung transplantation; Sarcoma; Scleroderma, Systemic; Silicosis; Small Cell Lung Carcinoma; Solid tumours; systemic sclerosis-associated interstitial lung disease; Telangiectasia, Hereditary Hemorrhagic; Uterine Neoplasms | Details |
| Tivozanib | KRN-951; KHK-4951; KHK4951; UNII-172030934T; ASP-4130; Kil-8951; AV-951 | Approved | Kyowa Hakko Kirin Co Ltd | Fotivda, FOTIVDA | EU | Carcinoma, Renal Cell | Recordati Netherlands BV | 2017-08-24 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Neoplasms; Hepatic Insufficiency; Metastatic breast cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma; Solid tumours; Triple Negative Breast Neoplasms; Wet Macular Degeneration | Details |
| Selpercatinib | LOXO-292; LY-3527723; ARRY-192; Ret-IN-1 | Approved | Array Biopharma | Retevmo, Retsevmo, 睿妥 | United States | Medullary thyroid cancer (MTC); Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung | Eli Lilly And Company | 2020-05-08 | Anorexia; Cachexia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colonic Neoplasms; Ependymoma; Fibrosarcoma; Glioma; Hematologic Neoplasms; Hepatic Insufficiency; Hepatoblastoma; Histiocytosis, Langerhans-Cell; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Medullary thyroid cancer (MTC); Medulloblastoma; Myofibromatosis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Poorly Differentiated Thyroid Gland Carcinoma; Renal Insufficiency; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Solid tumours; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Wilms Tumor | Details |
| Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; SU-010398; SU-11248; GB-102; PHA-290940; PNU-290940; SU-011248-L-malate salt | Approved | Pfizer Inc | Sutent, 索坦 | United States | Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell | Cppi Cv | 2006-01-26 | Abdominal Neoplasms; Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenocortical Carcinoma; AIDS-Related Complex; Amyloidosis; Angioimmunoblastic T-cell Lymphoma; Astrocytoma; Barrett Esophagus; Brain metastases; Brain Neoplasms; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Carcinoma, Acinar Cell; Carcinoma, Adenoid Cystic; Carcinoma, Adenosquamous; Carcinoma, Embryonal; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Choriocarcinoma; Chronic eosinophilic leukemia (CEL); Cognition Disorders; Colorectal Neoplasms; Diabetic macular oedema; Endodermal Sinus Tumor; Endometrial Neoplasms; Ependymoma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Fibrosarcoma; Gastrointestinal Stromal Tumors; Germinoma; Glioblastoma; Glioma; Gliosarcoma; Head and Neck Neoplasms; Hemangi | Details |
| Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Adenocarcinoma, Follicular; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Embryonal; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Chondrosarcoma; Chondrosarcoma, Extraskeletal Myxoid; Choriocarcinoma; Colorectal Neoplasms; Dermatofibrosarcoma; Endodermal Sinus Tumor; Epistaxis; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Gastrinoma; Gastroenteropancreatic neuroendocrine tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Germinoma; Glioblastoma; Glioma; Gliosarcoma; Glucagonoma; Hemangiosarcoma; Herpes Genitalis; Herpes Simplex; HIV Infections; Hormone-Resistant Prostate Neoplasms; Insulinoma; Leiomyosarcoma; Leukemia, Myeloid, Acute; Liposarcoma; Lung Neoplasms; Lymphoma; Macular Degeneration; Medullary thyroid cancer (MTC); Melanoma; Mesothelioma; Multiple Endocrine Neoplasia T | Details |
| Chloropyramine Hydrochloride | C9; C10; C9A; Y15; CFAK-C4; CFAK-C9; CFAK-C10; CFAK-Y15; CFAK-C9a | Approved | Synopen, Supralgon, Suprastin | Asthma; Conjunctivitis, Allergic; Rhinitis, Allergic | Details | |||||
| Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Astrocytoma; Bile Duct Neoplasms; Bone metastases; Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Glioblastoma; Glioma; Gliosarcoma; Hepatic Insufficiency; Hepatoblastoma; HIV Infections; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Lymphoma; Medullary thyroid cancer (MTC); Melanoma; Meningioma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroendocrin | Details |
| Fruquintinib | HMPL-013; TAK-113 | Approved | FRUZAQLA, Aiyoute, Elunate, 爱优特 | Mainland China | Colorectal Neoplasms | Hutchison Medipharma Ltd | 2018-09-04 | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Hepatic Insufficiency; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Renal Insufficiency; Sarcoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details | |
| Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Abdominal Neoplasms; Adenocarcinoma; Angioimmunoblastic T-cell Lymphoma; Astrocytoma; Bile Duct Neoplasms; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Burkitt Lymphoma; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Cholangiocarcinoma; Colonic Neoplasms; Esophageal Neoplasms; Facial Neoplasms; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Gallbladder Neoplasms; Gastrinoma; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Gliosarcoma; Glucagonoma; Head and Neck Neoplasms; Heart Arrest; Hemangiosarcoma; Hepatopulmonary Syndrome; Histiocytoma, Malignant Fibrous; Hypertension, Portal; Hypopharyngeal Neoplasms; Insulinoma; Kidney Diseases; Kidney Neoplasms; Laryngeal Diseases; Laryngeal Neoplasms; Leiomyosarcoma; Leukemia, Basophilic, Acute; Leukemia, Eosin | Details |
| Famitinib Malate | SHR-1020 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾比特 | Mainland China | Uterine Cervical Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2025-05-27 | Adenocarcinoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Metastatic breast cancer; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic neuroendocrine tumors (pNET); Small Cell Lung Carcinoma; Solid tumours; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland